Evidence map›Paper›PMID 38571495›Full record

ReviewFrontiers in oncology2024

Prospects and challenges of CAR-T cell therapy combined with ICIs.

Yufan Lv, Xinyu Luo, Zhuoyi Xie, Jieya Qiu, Jinsai Yang, Yuqi Deng, Rou Long, Guiyang Tang, Chaohui Zhang, Jianhong Zuo

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yufan LvThe Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Xinyu LuoThe Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Zhuoyi XieTransformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jieya QiuTransformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jinsai YangComputer Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yuqi DengTransformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Rou LongTransformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Guiyang TangTransformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Chaohui ZhangThe Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Jianhong ZuoThe Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology. Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.

Indexed as

CAR-T cellscombination therapyimmune checkpointsimmunotherapysolid tumors

Identifiers

PMID38571495
PMCPMC10989075
OpenAlexW4393001462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.